<div id="readability-page-1"><p><strong>Agilon Health Inc. <span>( AGL )</span></strong> shares are trading lower Friday. The move follows a massive Thursday rally where the stock soared over 100%. Traders appear to be taking profits after the company crushed quarterly expectations.</p>    <p>The Nasdaq is up 1.75% while the S&amp;P 500 has gained 0.72%.</p>    <h2>Wells Fargo Boosts Price Forecast</h2>    <p>Despite the Friday dip, analysts remain optimistic about the company’s trajectory. <strong>Wells Fargo </strong>maintained an Overweight rating on Agilon Health <span>( AGL )</span>. Wells Fargo raised the price forecast from $37.5 to $72.</p>    <p>This update followed the company’s upbeat 2026 guidance.</p>    <h2>Profit Taking After Record Gains</h2>    <p>The stock’s decline on Friday represents a natural correction. Retail traders are likely locking in gains from that surge. The rally was fueled by first-quarter earnings of $1.80 per share. This beat the $1.31 consensus estimate.</p>    <h2>Operational Initiatives Drive Sentiment</h2>    <p>The analyst focus remains on the company’s Total Care Model. Executive Chairman <strong>Ronald Williams</strong> noted the company is seeing early returns from investments in data and technology. Sales reached $1.42 billion, surpassing Wall Street’s $1.38 billion forecast.</p>    <h2>Agilon Health Raises Outlook</h2>    <p>Agilon raised its fiscal 2026 sales guidance to a range of $5.68 billion to $5.81 billion. This sits well above the $5.45 billion consensus. While membership decreased to 536,000, medical margins improved to $149 million.</p>    <h2>Agilon Health Price Action</h2>    <p><strong>AGL Stock Price Activity:</strong> Agilon Health <span>( AGL )</span> shares were down 11.52% at $53.67 at the time of publication on Friday, according to Benzinga Pro data.</p>    <p><em>Photo by Piotr Swat via Shutterstock</em></p></div>

<p>Agilon Health Inc. (AGL) shares fell 11.52% to $53.67 on Friday after a significant rally of over 100% the previous day. Traders are taking profits following strong quarterly earnings that exceeded expectations. Despite the dip, Wells Fargo maintained an Overweight rating and raised the price forecast from $37.5 to $72, citing positive 2026 guidance. Agilon's sales reached $1.42 billion, surpassing forecasts, and the company raised its fiscal 2026 sales outlook to $5.68-$5.81 billion, above the consensus of $5.45 billion.</p>

fidelity

agilon health

iShares US Healthcare Providers

VG Health

Health Care Select Sector SPDR

NASDAQ Composite Index

S&P 500

Wells Fargo

Shutterstock

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

What's Going On With Agilon Health Stock Friday?